Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPN01195 monotherapy first-in-human study in advanced solid tumours
2024-519184-18-00Phase 2Authorised
- Sponsor
- Ipsen
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of IPN01195 in Nonhematologic neoplasms (2 arms), sponsored by Ipsen. Primary endpoints: Percentage of participants with dose limiting toxicity, Percentage of participants experiencing treatment-emergent serious adverse events and 2 more. Planned start May 2025; status: authorised.
02
Drugs
IPN01195
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-519184-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519184-18-00.